Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print   

Friday 19 March, 2021

Oxford Biomedica PLC

Update on Sanofi Collaboration & License Agreement

RNS Number : 8403S
Oxford Biomedica PLC
19 March 2021
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

Oxford Biomedica announces that Sanofi intends to terminate the Collaboration and License Agreement in the field of haemophilia gene therapy

 

 

Oxford, UK - 19 March, 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announced today that Sanofi has given notice that they intend to terminate the Collaboration and License Agreement for process development and manufacturing of lentiviral vectors to treat haemophilia.

 

Oxford Biomedica had originally signed the Collaboration and License Agreement with Bioverativ (which was acquired by Sanofi) in February 2018.

 

The Group expects that the impact on revenue will be negligible over the coming 24 month period.

 

 

 

-Ends-

Enquiries:

 

 

Oxford Biomedica plc

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Catherine Isted, Head of Corporate Development & IR

 

 

 

 

T: +44 (0)1865 783 000

T: +44 (0)1865 783 000

T: +44 (0)1865 954 161 / E: [email protected]

 

 

Consilium Strategic Communications

 

Mary-Jane Elliott/Matthew Neal

 

 

 

T: +44 (0)20 3709 5700

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com

 

 

 

The person who arranged for the release of this announcement on behalf of Oxford Biomedica plc was John Dawson, Chief Executive Officer.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCJLMFTMTABMLB

a d v e r t i s e m e n t